71 results
Page 2 of 4
8-K
EX-1.1
48plzu5hm98p
27 Apr 22
Agile Therapeutics Announces 1-FOR-40 Reverse Stock Split
7:21am
424B5
76oqgsvy80xvrghf
27 Apr 22
Prospectus supplement for primary offering
6:30am
424B5
l5g csoexvn
14 Mar 22
Prospectus supplement for primary offering
5:26pm
8-K
EX-1.1
c5auv
10 Jan 22
Entry into a Material Definitive Agreement
8:05am
8-K
EX-99.1
9o3t yu88bx
10 Jan 22
Entry into a Material Definitive Agreement
8:05am
424B5
x7inp36 yz
10 Jan 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
fjx7c5mn3vrz
2 Nov 21
Agile Therapeutics Reports Third Quarter 2021 Financial Results
4:11pm
424B5
qs5d8de
8 Oct 21
Prospectus supplement for primary offering
5:21pm
424B5
srfquc
7 Oct 21
Prospectus supplement for primary offering
5:24pm
8-K
EX-99.1
h5loinx1xj7tdtjt
4 Oct 21
Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary
4:30pm
8-K
EX-1.1
e8xi2x zh8k
18 Mar 21
Entry into a Material Definitive Agreement
5:13pm
424B5
m8spplg
18 Mar 21
Prospectus supplement for primary offering
5:01pm